CL2015003013A1 - Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina - Google Patents

Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina

Info

Publication number
CL2015003013A1
CL2015003013A1 CL2015003013A CL2015003013A CL2015003013A1 CL 2015003013 A1 CL2015003013 A1 CL 2015003013A1 CL 2015003013 A CL2015003013 A CL 2015003013A CL 2015003013 A CL2015003013 A CL 2015003013A CL 2015003013 A1 CL2015003013 A1 CL 2015003013A1
Authority
CL
Chile
Prior art keywords
gonadotropin
receptor antagonists
hormone receptor
releasing hormone
spiroindoline
Prior art date
Application number
CL2015003013A
Other languages
English (en)
Inventor
Panknin Olaf
Ring Sven
Bäurle Stefan
Wagenfeld Andrea
Nubbemeyer Reinhard
Nowak-Reppel Katrin
Langer Gernot
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48047908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015003013(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2015003013A1 publication Critical patent/CL2015003013A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

COMPUESTOS DERIVADOS DE ESPIROINDOLINA, PROCESOS PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS CON LOS MISMOS, SU USO PARA EL TRATAMIENTO DE ENFERMEDADES Y SU USO EN LA ELABORACIÓN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES, EN ESPECIAL ENFERMEDADES RELACIONADAS CON LAS HORMONAS SEXUALES, TANTO EN HOMBRES COMO EN MUJERES, EN PARTICULAR AQUELLAS SELECCIONADAS DEL GRUPO DE ENDOMETRIOSIS, LEIOMIOMA UTERINO (FIBROIDES), ENFERMEDAD DE OVARIO POLIQUÍSTICO, MENORRAGIA, DISMENORREA, HIRSUTISMO, PUBERTAD .
CL2015003013A 2013-04-09 2015-10-09 Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina CL2015003013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13162986 2013-04-09

Publications (1)

Publication Number Publication Date
CL2015003013A1 true CL2015003013A1 (es) 2016-04-08

Family

ID=48047908

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003013A CL2015003013A1 (es) 2013-04-09 2015-10-09 Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina

Country Status (28)

Country Link
US (1) US20160052936A1 (es)
EP (1) EP2984092A1 (es)
JP (1) JP2016519104A (es)
KR (1) KR20150139917A (es)
CN (1) CN105308053A (es)
AP (1) AP2015008822A0 (es)
AR (1) AR095785A1 (es)
AU (1) AU2014253232A1 (es)
BR (1) BR112015025700A2 (es)
CA (1) CA2908869A1 (es)
CL (1) CL2015003013A1 (es)
CR (1) CR20150530A (es)
CU (1) CU20150141A7 (es)
DO (1) DOP2015000259A (es)
EA (1) EA201501000A1 (es)
HK (1) HK1216101A1 (es)
IL (1) IL241067A0 (es)
MA (1) MA38463B1 (es)
MX (1) MX2015014267A (es)
NI (1) NI201500149A (es)
PE (1) PE20160007A1 (es)
PH (1) PH12015502318A1 (es)
SG (1) SG11201506962TA (es)
TN (1) TN2015000453A1 (es)
TW (1) TW201518304A (es)
UY (1) UY35526A (es)
WO (1) WO2014166958A1 (es)
ZA (1) ZA201508209B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634418A1 (en) 2017-06-05 2020-04-15 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0213715D0 (en) * 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
EA201491344A1 (ru) * 2012-01-16 2015-04-30 Байер Интеллектуэль Проперти Гмбх Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона

Also Published As

Publication number Publication date
AP2015008822A0 (en) 2015-10-31
HK1216101A1 (zh) 2016-10-14
NI201500149A (es) 2015-11-30
WO2014166958A1 (en) 2014-10-16
CA2908869A1 (en) 2014-10-16
TN2015000453A1 (en) 2017-04-06
PH12015502318A1 (en) 2016-02-15
TW201518304A (zh) 2015-05-16
BR112015025700A2 (pt) 2017-07-18
AR095785A1 (es) 2015-11-11
UY35526A (es) 2014-11-28
IL241067A0 (en) 2015-11-30
KR20150139917A (ko) 2015-12-14
MA38463B1 (fr) 2018-11-30
EA201501000A1 (ru) 2016-04-29
CU20150141A7 (es) 2016-03-31
CN105308053A (zh) 2016-02-03
US20160052936A1 (en) 2016-02-25
DOP2015000259A (es) 2015-11-15
SG11201506962TA (en) 2015-10-29
CR20150530A (es) 2016-01-29
MX2015014267A (es) 2016-03-01
MA38463A1 (fr) 2018-05-31
ZA201508209B (en) 2018-05-30
PE20160007A1 (es) 2016-02-14
EP2984092A1 (en) 2016-02-17
JP2016519104A (ja) 2016-06-30
AU2014253232A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015002098A1 (es) “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CU20160087A7 (es) Indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen
CL2016000922A1 (es) Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
BR112017015310A2 (pt) uso de pgr4 como um agente anti-inflamatório
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
GT201400153A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
BR112015030387A8 (pt) compostos de pirazol moduladores de fshr, seu processo de fabricação, composição farmacêutica que os compreende, bem como uso dos mesmos
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
UY35293A (es) Isotiazoles sustituidos con amino
UY33470A (es) Derivados de 6,7-dihidro-5h-benzo[7]anulenos, métodos para su preparación, preparaciones farmacéuticas que los contienen y su uso para la preparación de medicamentos
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer